Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 9 (31), 1197-1204

Hepatic Hydrothorax: An Update and Review of the Literature


Hepatic Hydrothorax: An Update and Review of the Literature

Dmitry Victorovich Garbuzenko et al. World J Hepatol.


This review considers the modern concepts of pathogenesis, diagnostic methods, and treatment principles of hepatic hydrothorax (HH). HH is the excessive (> 500 mL) accumulation of transudate in the pleural cavity in patients with decompensated liver cirrhosis but without cardiopulmonary and pleural diseases. It causes respiratory failure which aggravates the clinical course of liver cirrhosis, and the emergence of spontaneous bacterial pleural empyema may be the cause of death. The information was collected from the PubMed database, the Google Scholar retrieval system, the Cochrane reviews, and the reference lists from relevant publications for 1994-2016 using the keywords: "liver cirrhosis", "portal hypertension", "hepatic hydrothorax", "pathogenesis", "diagnostics", and "treatment". To limit the scope of this review, only articles dealing with uncomplicated hydrothorax in patients with liver cirrhosis were included. The analysis of the data showed that despite the progress of modern hepatology, the presence of HH is associated with poor prognosis and high mortality. Most patients suffering from it are candidates for orthotopic liver transplantation. In routine clinical practice, stratification of the risk for an adverse outcome and the subsequent determination of individual therapeutic strategies may be the keys to the successful management of the patient's condition. The development of pathogenetic pharmacotherapy and optimization of minimally invasive treatment will improve the quality of life and increase the survival rate among patients with HH.

Keywords: Diagnostics; Hepatic hydrothorax; Liver cirrhosis; Portal hypertension; Treatment.

Conflict of interest statement

Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.


Figure 1
Figure 1
Pathogenetic mechanisms and treatment principles of hepatic hydrothorax. LVP: Large-volume paracentesis; TIPS: Transjugular intrahepatic portosystemic shunt.

Similar articles

See all similar articles

Cited by 3 articles


    1. Porcel JM. Identifying transudates misclassified by Light’s criteria. Curr Opin Pulm Med. 2013;19:362–367. - PubMed
    1. Abbasi A, Bhutto AR, Alam MT, Aurangzaib M, Masroor M. Frequency of Hepatic Hydrothorax and its Association with Child Pugh Class in Liver Cirrhosis Patients. J Coll Physicians Surg Pak. 2016;26:566–569. - PubMed
    1. Garbuzenko DV. Pathophysiological mechanisms and new directions of therapy of portal hypertension at liver cirrhosis. Klin Persp Gastrojen Gepatol. 2010;6:11–20.
    1. Pedersen JS, Bendtsen F, Møller S. Management of cirrhotic ascites. Ther Adv Chronic Dis. 2015;6:124–137. - PMC - PubMed
    1. Lazaridis KN, Frank JW, Krowka MJ, Kamath PS. Hepatic hydrothorax: pathogenesis, diagnosis, and management. Am J Med. 1999;107:262–267. - PubMed